Bimiralisib Withdrawn Phase 2 Trials for Primary Central Nervous System Lymphoma Treatment

IndicationsStatusPurposePhase
WithdrawnTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT03120000PQR309 in Phase 2 in Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma